

# Most dogs require just a single tablet or half-tablet daily

NUMELVI is administered orally, once daily, at or around mealtime at a dose of 0.8 -1.2 mg per kg (0.36 -0.54 mg per lb) body weight according to the dosing table below.

Body weight of dog		Strength of NUMELVI tablets to be administered			
lb	kg	4.8 mg	7.2 mg	21.6 mg	31.6 mg
4.4–6.5	2.0–2.9	½			
6.6–9.5	3.0–4.3		½		
9.6–13.3	4.4–6.0	1			
13.4–19.9	6.1–9.0		1		
20.0–29.8	9.1–13.5			½	
29.9–42.6	13.6–19.3				½
42.7–58.4	19.4–26.5			1	
58.5–87.0	26.6–39.5				1
87.1–118.9	39.6–54.0				1 ½
119.0–174.2*	54.1–79.0*				2

\* For dogs ≥ 174.3 lb (≥79.1 kg), administer the appropriate combination of tablets strengths to achieve the target dose of 0.8-1.2 mg/kg.

\*\* In a canine interleukin-31 (cIL-31)-induced pruritus model.



**Numelvi™**  
(atinivicitinib tablets)

The Future of Itch Relief



Safe for dogs and puppies as young as 6 months of age



Itch relief starts in 2 to 4 hours<sup>\*\*</sup>



Once-daily dosing from day 1

**References:** T. Kowalski T, Prohaczik A, Locke K, Samson C, Hope K. (2026) The second-generation Janus kinase inhibitor atinivicitinib significantly reduces pruritus 2-4 hours after dosing dogs in a canine interleukin-31 model. *Veterinary Dermatology*. 2026; <https://doi.org/10.1111/vde.70046>

**Important Safety Information:** NUMELVI is not for use in dogs less than 6 months of age or those with serious infections. NUMELVI may increase susceptibility to opportunistic infections, including demodicosis and interdigital furunculosis. Consider the risks and benefits of treatment prior to initiating NUMELVI in dogs with a history of recurrent demodicosis. NUMELVI is a JAK inhibitor. New neoplastic conditions (benign and malignant) have been reported in dogs treated with other JAK inhibitors. The effectiveness and safety of NUMELVI have not been evaluated in a field study beyond 28 days. The safe use of NUMELVI has not been evaluated in breeding, pregnant, or lactating dogs, nor in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents. For complete safety information, refer to the product label.

Copyright © 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. US-NUM-250800007